文献速递临床试验与 GCP新药、器械与细胞基因治疗研发

同种异体记忆T细胞或NK细胞治疗COVID-19肺炎和/或淋巴细胞减少的I/II期剂量递增多中心研究:RELEASE试验方案

A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol.
PubMed 文献 · Trials · 2021-10-02

RELEASE研究是一项开放标签、多中心、双臂、随机、剂量探索的I/II期临床试验,评估同种异体记忆T细胞和NK细胞治疗伴淋巴细胞减少和/或肺炎的COVID-19患者的安全性、耐受性、同种反应性和疗效。I期纳入18例无需吸氧或经鼻导管吸氧≤2.5升/分的患者,II期计划纳入182例无需机械通气的患者,分别比较记忆T细胞或NK细胞联合标准治疗与单独标准治疗。

要点

  • I期评估递增剂量记忆T细胞或NK细胞联合标准治疗的安全性。
  • II期随机比较推荐2期剂量联合标准治疗与单独标准治疗。
  • 研究对象为伴淋巴细胞减少和/或肺炎的COVID-19患者。

核心结论

  • 假设从COVID-19康复供者获取的SARS-CoV-2特异性记忆T淋巴细胞可作为被动细胞免疫治疗,用于治疗中/重度患者的肺炎和淋巴细胞减少。

研究设计与样本

  • 开放标签、多中心、双臂、随机、剂量探索的I/II期临床试验。
  • I期纳入18例COVID-19相关肺炎和/或淋巴细胞减少、无需吸氧或经鼻导管吸氧≤2.5升/分的患者,按供者和患者生物学特征分配至A臂或B臂。
  • II期计划纳入182例COVID-19相关肺炎和/或淋巴细胞减少、需要或不需氧疗但无需机械通气的患者,考虑HLA配型分配至A臂或B臂,臂内按1:1随机。

关键数值与推荐

  • A臂治疗为递增剂量记忆T细胞联合标准治疗(I期),或推荐2期剂量记忆T细胞联合标准治疗对比单独标准治疗(II期)。
  • B臂治疗为递增剂量NK细胞联合标准治疗(I期),或推荐2期剂量NK细胞联合标准治疗对比单独标准治疗(II期)。
  • I期患者吸氧条件为无需吸氧或经鼻导管吸氧≤2.5升/分。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND: Moderate/severe cases of COVID-19 present a dysregulated immune system with T cell lymphopenia and a hyper-inflammatory state. This is a study protocol of an open-label, multi-center, double-arm, randomized, dose-finding phase I/II clinical trial to evaluate the safety, tolerability, alloreactivity, and efficacy of the administration of allogeneic memory T cells and natural killer (NK) cells in COVID-19 patients with lymphopenia and/or pneumonia. The aim of the study is to determine the safety and the efficacy of the recommended phase 2 dose (RP2D) of this treatment for patients with moderate/severe COVID-19. METHODS: In the phase I trial, 18 patients with COVID-19-related pneumonia and/or lymphopenia with no oxygen requirement or with an oxygen need of ≤ 2.5 liters per minute (lpm) in nasal cannula will be assigned to two arms, based on the biology of the donor and the patient. Treatment of arm A consists of the administration of escalating doses of memory T cells, plus standard of care (SoC). Treatment of arm B consists of the administration of escalating doses of NK cells, plus SoC. In the phase II trial, a total of 182 patients with COVID-19-related pneumonia and/or lymphopenia requiring or not oxygen supplementation but without mechanical ventilation will be allocated to arm A or B, considering HLA typing. Within each arm, they will be randomized in a 1:1 ratio. In arm A, patients will receive SoC or RP2D for memory T cells plus the SoC. In arm B, patients will receive SoC or RP2D for NK cells plus the SoC. DISCUSSION: We hypothesized that SARS-CoV-2-specific memory T-lymphocytes obtained from convalescent donors recovered from COVID-19 can be used as a passive cell immunotherapy to treat pneumonia and lymphopenia in moderate/severe patients. The lymphopenia induced by COVID-19 constitutes a therapeutic window that may facilitate donor engraftment and viral protection until recovery. TRIAL REGISTRATION: ClinicalTrials.gov NCT04578210 . First Posted : October 8, 2020.

来源:Trials,查看原文。版权归原作者所有。

引用

  1. García-García I, Guerra-García P, Ferreras C, et al. A phase I/II dose-escalation multi-center study to evaluate the safety of infusion of natural killer cells or memory T cells as adoptive therapy in coronavirus pneumonia and/or lymphopenia: RELEASE study protocol. Trials. 2021. PMID: 34600562. doi:10.1186/s13063-021-05625-7

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。